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Abstract
Background Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate 
long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Objective To evaluate the cost effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients 
in England.
Methods A Markov state-transition model was developed to estimate the lifetime costs and benefits of nivolumab versus 
ipilimumab and dacarbazine for BRAF mutation-negative patients and versus ipilimumab, dabrafenib, and vemurafenib for 
BRAF mutation-positive patients. Covariate-adjusted parametric curves for time to progression, pre-progression survival, 
and post-progression survival were fitted based on patient-level data from two trials and long-term ipilimumab survival data. 
Indirect treatment comparisons between nivolumab, ipilimumab, and dacarbazine were informed by these covariate-adjusted 
parametric curves, controlling for differences in patient characteristics. Kaplan–Meier data from the literature were digitised 
and used to fit progression-free and overall survival curves for dabrafenib and vemurafenib. Patient utilities and resource 
use data were based on trial data or the literature. Patients are assumed to receive nivolumab until there is no further clinical 
benefit, assumed to be the first of progressive disease, unacceptable toxicity, or 2 years of treatment.
Results Nivolumab is the most cost-effective treatment option in BRAF mutation-negative and mutation-positive patients, 
with incremental cost-effectiveness ratios of £24,483 and £17,362 per quality-adjusted life year, respectively. The model 
results are most sensitive to assumptions regarding treatment duration for nivolumab and the parameters of the fitted para-
metric survival curves.
Conclusions Nivolumab is a cost-effective treatment for advanced melanoma patients in England.
Keywords Nivolumab · Cost-effectiveness · Economic evaluation · Advanced melanoma
JEL Classification I19
Introduction
Melanoma is an aggressive type of skin cancer representing 
4% of all UK skin cancer cases but 90% of all skin cancer-
related deaths [1]. For patients with advanced melanoma 
(unresectable or metastatic disease), historically prognosis 
has been poor, with a median survival of 6–10 months [2–6] 
and a 5-year survival around 10% [3, 5, 7].
Until recently in England, treatments available for 
advanced melanoma included ipilimumab and dacarbazine 
(mainly for patients who are ineligible for or unresponsive to 
ipilimumab) for patients without a BRAF mutation or BRAF 
wild-type (BRAF −ve). For patients with a BRAF mutation 
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(BRAF +ve), ipilimumab and BRAF inhibitors (dabrafenib or 
vemurafenib) were standard treatments. Despite more recent 
therapeutic advances with ipilimumab, the long-term survival 
of many advanced melanoma patients remains elusive [8], 
with consequences felt by patients, caregivers, and society.
Ipilimumab offers potential long-term survival for ~ 20% 
of advanced melanoma patients, but not all patients respond, 
and there is a strong correlation between induction therapy 
completion and long-term survival with ipilimumab [9]. 
Alternatives target BRAF mutations, including dabrafenib 
and vemurafenib, but their clinical benefit is generally short-
lived, with patients demonstrating progressive disease within 
5–8  months of therapy initiation [10–12]. Importantly, 
BRAF mutations are only observed in approximately 50% 
of melanoma tumours [13]. For advanced melanoma patients 
who are ineligible for, or unresponsive to, ipilimumab or 
BRAF inhibitors, there were no alternative treatment options 
outside of palliative chemotherapy such as dacarbazine until 
recently in England.
Nivolumab is a fully human, monoclonal immunoglobu-
lin G4 antibody that acts as a programmed death receptor 1 
(PD-1) checkpoint inhibitor; blocking the interaction of PD-1 
with its ligands PD-L1 and PD-L2 [14]. The mechanism of 
action for nivolumab is different from BRAF inhibitors. Simi-
lar to ipilimumab, nivolumab stimulates the patient’s own 
immune system to directly fight cancer cells (as it would 
any other ‘foreign’ cell), resulting in the destruction of the 
tumour through pre-existing, intrinsic processes. The spe-
cific mechanism of action of immuno-oncology therapy has 
important implications for the duration of treatment required 
and the long-term survival profile expected. Nivolumab and 
ipilimumab act via distinct pathways, but both elicit immune 
memory, and thereby potentially promote long-term survival.
Based on efficacy and safety results from clinical stud-
ies including the pivotal Phase III randomised controlled 
trial (RCT), CheckMate 066, nivolumab monotherapy was 
approved by the European Medicines Agency (EMA) for 
a marketing authorisation in June 2015 for the treatment 
of advanced (unresectable or metastatic) melanoma. The 
National Institute for Health and Care Excellence (NICE) 
subsequently appraised nivolumab within its licensed indica-
tion, and a positive recommendation was issued in February 
2016 [15]. This article is based on the economic analysis 
performed for the NICE appraisal.
Pembrolizumab, another PD-1 checkpoint inhibitor, was 
not considered a relevant comparator in the analysis because 
of the overlap in timing of the two appraisal processes; 
nivolumab was not a comparator in the pembrolizumab 
appraisal [16, 17].
Thus, the overall objective of the analysis was to evalu-
ate the cost-effectiveness of nivolumab monotherapy for the 
treatment of advanced melanoma patients in England. BRAF 
mutation status was used to define two groups of patients, 
with ipilimumab and dacarbazine as the comparators for 
the BRAF −ve subgroup, and ipilimumab, dabrafenib, and 
vemurafenib as the comparators for the BRAF +ve sub-
group; this division also allowed patient characteristics 
to vary between groups. The analyses for BRAF −ve and 
BRAF +ve patient subgroups are performed separately.
In performing such an analysis, apart from the com-
mon challenges for developing oncology cost-effectiveness 
models (e.g., choosing the method for modelling survival, 
selecting the most appropriate parametric survival curves, 
and extrapolating survival based on a relatively short trial 
period), there are additional challenges specific to model-
ling immunotherapy. These include modelling a group of 
patients who may have longer overall survival (OS) when 
treated with immunotherapy, but without long-term data 
for the new immunotherapy treatment (i.e., nivolumab). 
Another challenge specific to immunotherapy is ‘pseudo-
progression’, where patients who ultimately have good OS 
have tumours that enlarge when assessed in the early stages 
of treatment, meeting the criteria for ‘progressed disease’ 
as assessed by the Response Evaluation Criteria In Solid 
Tumours (RECIST) criteria. This creates issues regarding 
the use of progression-free survival (PFS) for modelling 
survival, utilities, and resource use for immunotherapies.
Methods
Overview
A semi-Markov state-transition model was developed, where 
health-states were defined by four different measures rel-
evant to the evaluation of the clinical and cost-effectiveness 
of nivolumab (see Fig. 1 for a simplified model structure):
• Progression status for modelling survival and utility: pro-
gression free, progressed, and dead.
• Time to death for modelling utility: ≥ 30 days before 
death and < 30 days before death.
• Time since treatment initiation and time to death for 
modelling resource use: first/second/third year after 
treatment initiation and 12 weeks before death (pallia-
tive care); and death.
• Treatment status for modelling nivolumab drug cost: on 
treatment and off treatment.
Utilities were modelled based on both progression status 
and time to death (≥ 30 and < 30 days before death). The 
standard progression-based utility approach has the limita-
tion of not being able to capture the decline of cancer patient 
utilities towards the end of life. The previous studies have 
quantified the independent impact of time to death on can-
cer patient utilities, which were found to decline towards 
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death [18–20]. Another reason for choosing a more com-
plex method for modelling utility is the pseudo-progression 
experienced by some patients treated with immunotherapies 
(e.g., nivolumab and ipilimumab). The use of time to death 
utilities can mitigate the uncertainties of modelling utilities 
only based on progression status.
The rationale for using time since treatment initiation 
and time to death for modelling resource use is similar for 
utility modelling in that it better captures the resource use 
for advanced melanoma patients, given the long OS experi-
enced and expected for these patients with immunotherapies, 
including nivolumab and ipilimumab [9].
The same model structure is applied to both BRAF −ve 
and BRAF +ve patients. The methods used for the compari-
son between nivolumab, ipilimumab, and dacarbazine for the 
BRAF −ve patient population are presented in the remainder 
of this section. The comparison of nivolumab with BRAF 
inhibitors (dabrafenib and vemurafenib) for the BRAF +ve 
patient population is presented in Supplemental Materials.
Key aspects of the modelling methods, assumptions, and 
inputs were validated by UK health economics and clinical 
experts.
Modelling survival and safety
There are two main approaches to implementing a three-state 
model: an area-under-the-curve (AUC) partitioned survival 
approach and a state-transition approach. The AUC approach 
directly estimates proportions of progression-free, pro-
gressed, and dead patients based on the OS and PFS curves. 
Under the state-transition approach, transition probabilities 
are used to estimate the proportions of progression-free, pro-
gressed, and dead patients over time.
In this analysis, the state-transition approach was used 
for nivolumab, ipilimumab, and dacarbazine by fitting 
covariate-adjusted parametric curves based on patient-level 
data for time to progression (TTP), pre-progression survival 
(PrePS), and post-progression survival (PPS). These curves 
were then used to derive time-dependent transition prob-
abilities. For the BRAF inhibitors, the AUC approach was 
used by directly fitting OS and PFS curves using digitised 
Kaplan–Meier (KM) data published in the literature (see 
Supplemental Materials for details). In both cases, long-term 
survival data from non-RCT sources were also used for mod-
elling survival beyond the trial period.
Indirect treatment comparison for nivolumab, ipilimumab, 
and dacarbazine
Nivolumab, ipilimumab, and dacarbazine have not been 
investigated together in a single clinical trial; however, 
patient-level data are available from two Phase III RCTs for 
advanced melanoma patients. The CheckMate 066 trial is 
a Phase III RCT for nivolumab monotherapy using dacar-
bazine as the control [21]. MDX010-020 is a Phase III RCT 
for ipilimumab and ipilimumab + gp100 using gp100 as the 
control [22]. The comparative efficacy of nivolumab and 
ipilimumab was established via a common comparator of 
pooled dacarbazine and gp100 and assuming the same effi-
cacy between the two treatments, which is supported by the 
literature [2, 23, 24] and decision by NICE for ipilimumab 
[25]. To enlarge the sample size, patients in the ipilimumab 
and ipilimumab + gp100 arms in MDX010-020 were pooled 
to represent ipilimumab monotherapy, which is also sup-
ported by the trial results [26].
The indirect treatment comparison between nivolumab, 
ipilimumab, and dacarbazine was implemented by fitting 
covariate-adjusted parametric curves for TTP, PrePS, and 
PPS using patient-level data from CheckMate 066 and 
MDX010-020. The covariate-adjusted statistical model 
Fig. 1  Economic model struc-
ture
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ensures that the differences of the covariates between the two 
trials and between different arms in each trial are accounted 
for when estimating the ceteris paribus comparative treat-
ment effects for nivolumab, ipilimumab, and dacarbazine. 
Covariates were selected based on the literature and clini-
cal relevance and include gender, age band, lactate dehy-
drogenase level, the Eastern Cooperative Oncology Group 
(ECOG) performance status, distant metastasis state, history 
of brain metastasis, and the use of ipilimumab as subsequent 
therapy. Finally, the fixed trial effect (CheckMate 066 vs 
MDX010-020) was included as a covariate that preserves 
trial randomisation and, thus, the validity of the indirect 
comparison between nivolumab and ipilimumab. The dis-
tribution of the covariates in different treatment arms and 
trials is presented in Supplemental Materials, and shows that 
these patient characteristics are comparable between treat-
ment arms within a trial but less comparable between trials. 
It also shows that there is good overlap of covariates among 
different treatment arms, which is required for fitting the 
covariate-adjusted statistical models.
The patient characteristics used in the model were based 
on mean values from CheckMate 066 for BRAF −ve patients 
and the vemurafenib arm of the BRIM-3 trial for BRAF +ve 
patients (see Table 1). The differences in patient characteris-
tics between BRAF −ve and BRAF +ve patients reflect the 
different prognostic factors seen in clinical practice.
The selection of the base case parametric curves for TTP, 
PrePS, and PPS was based on the guidance proposed by 
the NICE Decision Support Unit [27]. Gompertz and log-
logistic curves were selected as the base case for TTP (post-
100 days) and PPS, respectively, and are presented in Sup-
plemental Materials. For the first 100 days of TTP and for 
PrePS, none of the parametric curves has a good visual fit; 
therefore, KM data were used directly and adjusted by the 
hazard ratios for each of the covariates estimated based on 
a Cox proportional hazards model (see Supplemental Mate-
rials for the detailed adjustment method and the models). 
The final base case TTP, PrePS, and PPS curves are also 
presented in Supplemental Materials.
Modelling long‑term survival
Three sources of evidence were used to model long-term 
survival. First, for nivolumab and ipilimumab, the pooled 
ipilimumab long-term OS [9] was used in the model from 
Year 3 onwards. The ipilimumab pooled analysis is the only 
long-term OS evidence for immunotherapies for advanced 
melanoma patients, which showed a plateau in the OS 
beginning around Year 3, with follow-up to 10 years. The 
long-term ipilimumab OS is also assumed to be applica-
ble to nivolumab because of similarity of the mechanism 
of action (both are immunotherapies), supported by clini-
cal expert opinion. Second, registry OS for Stage IV mela-
noma reported by the American Joint Committee on Cancer 
(AJCC) [28], which has a follow-up period of 15 years, was 
used for the OS for the dacarbazine and BRAF inhibitor 
arms from Year 2 onwards. Finally, general population mor-
tality based on the latest life table in England was used as 
the background mortality in the model [29].
Published data from the pooled ipilimumab analysis 
and the AJCC registry were digitised and rebased at 3 and 
2 years to fit different types of parametric curves, where 
Gompertz and log-normal curves were chosen, respec-
tively, for the base case based on statistical fit and clinical 
plausibility.
Table 1  Patient’s characteristics 
used in the economic model
ECOG Eastern Cooperative Oncology Group, kg kilogram, LDH lactate dehydrogenase, m metre, PPS 
post-progression survival, PrePS pre-progression survival, TOT time on treatment, TTP time to progres-
sion, ULN upper limit of the normal range
a Based on CheckMate 066
b Based on BRIM-3
c Assumed the same as BRAF mutation-negative patients in the absence of data
BRAF mutation-
negativea
BRAF mutation-
positiveb
Use in the model
Mean age 63 56 Starting age in the model
% male 58.9% 59.0% TTP, PPS, PrePS, TOT
% under 65 47.8% 100% TTP, PPS, PrePS, TOT
Mean weight (kg) 78.7 78.7c Drug dosing
Mean body surface  (m2) 1.9 1.9c Drug dosing
% stage M1c 61.0% 66.0% TTP, PPS, PrePS, TOT
ECOG status = 0 64.5% 68.0% TTP, PPS, PrePS, TOT
% elevated LDH (> ULN) 36.6% 58.0% TTP, PPS, PrePS, TOT
% with brain metastases 3.6% 0% TTP, PPS, PrePS, TOT
% subsequent ipilimumab treatment 29.7% 22.0% PPS
The cost‑effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients…
1 3
Figure 2 presents the modelled OS for the entire time 
horizon based on PrePS, TTP, PPS, and long-term sur-
vival data for nivolumab, ipilimumab, and dacarbazine for 
BRAF −ve patients.
Safety
Patient-level adverse event (AE) data from CheckMate 
066 were used to calculate the proportion of patients in 
the nivolumab and dacarbazine arms that experience drug-
related endocrine disorders (any grade), diarrhoea (Grade 
2 +) and other AEs (Grade 3 +), with no restriction on the 
minimum proportion of patients experiencing an AE. The 
recorded hospitalisation (measured by hospital bed days) 
used for treating AEs and the proportion of patients requir-
ing outpatient visits were derived from the patient-level data 
and the literature [30] for the costing of AEs.
For ipilimumab, dabrafenib, and vemurafenib, where 
patient-level AE data were not available, CheckMate 067, 
BREAK-3, and BRIM-3 trial data were used to derive the 
comparable safety model inputs relative to nivolumab and 
dacarbazine.
Health‑related quality of life
To avoid total dependence of utility modelling on progres-
sion status and to account for the decline of utility with 
regard to time to death [18], a more complex method that 
captures both progression status and time to death was 
considered better suited for modelling utility in this analysis. 
The EQ-5D data collected in the pivotal CheckMate 066 trial 
were used in a longitudinal model with both progression sta-
tus and whether within 30 days of death as covariates, so that 
utility estimates can be obtained for all four combinations 
of progression status and time to death (e.g., progression 
free and more than 30 days from death). Detailed statistical 
model results are presented in Supplemental Materials.
The impact of AEs on health-related quality of life 
was modelled by applying utility decrements, which were 
based on the literature [31] and applied to the percentage of 
patients estimated to experience each category of the mod-
elled AEs.
Time on treatment and drug costs
Time on treatment (TOT) for nivolumab was modelled using 
covariate-adjusted parametric curves based on patient-level 
data from CheckMate 066. The method and choice of base 
case curve is the same as for the effectiveness endpoints, but 
only nivolumab data were used for fitting parametric curves 
(hence no treatment covariate). The log-logistic curve was 
chosen as the base case input based on statistical fit and 
clinical plausibility. For nivolumab, a maximum treatment 
duration of 2 years was deemed realistic in clinical practice 
in England by UK clinicians. Exploratory analysis from the 
nivolumab trials suggests that patients continue to respond 
long after discontinuation of treatment and that responding 
patients are unlikely to continue treatment with nivolumab 
Fig. 2  Overall survival in the base case model for BRAF mutation-negative analysis. DTIC dacarbazine, OS overall survival, PPS post-progres-
sion survival, PrePS pre-progression survival, TTP time to progression
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into the long term. Scenario analyses on the length of the 
maximum treatment duration and on the assumed propor-
tion of patients who discontinue treatment at 2 years were 
tested. The proportions of patients receiving each dose of 
ipilimumab were derived from the ipilimumab trials. For 
dacarbazine and BRAF inhibitors, it was assumed that treat-
ment continues until disease progression.
Drug dosing for nivolumab and comparators was based on 
the summaries of product characteristics. Drug wastage was 
considered in the model. For nivolumab and ipilimumab, 
the dosing based on the method of moments was applied 
to estimate the mean number of vials required using UK 
patient-level weight data from nivolumab and ipilimumab 
trials. All drug costs were sourced from the Monthly Index 
of Medical Specialities (MIMS) [32] and the electronic mar-
ket information tool (eMit) [33]. Ipilimumab, dabrafenib, 
and vemurafenib each has a separate patient access scheme 
(PAS), providing each drug at a discounted cost that is com-
mercially confidential. The known ipilimumab PAS (the 
same manufacturer as nivolumab) and the assumed PAS for 
dabrafenib and vemurafenib were used in the analysis, so 
that the estimated cost-effectiveness results were relevant 
to the reimbursement decision. Drug administration costs 
were based on the National Health Service (NHS) reference 
costs [34].
Resource use
The resource use quantity and frequency were sourced from 
the literature [6, 25] and updated according to UK clinical 
opinion to match current treatment practice in England. The 
length of palliative care is assumed to be 12 weeks based on 
clinical opinion. Unit costs were based on NHS reference 
costs.
One of the covariates for the fitted TTP curves is the pro-
portion of patients treated with ipilimumab as a subsequent 
line of therapy. As the subsequent use of ipilimumab affects 
survival, the corresponding costs were also included in the 
model and applied to a proportion of patients receiving ipili-
mumab as subsequent treatment (except in the ipilimumab 
arm). The mean number of ipilimumab cycles as subsequent 
treatment was based on a previous NICE appraisal [35].
A summary of the key base case model inputs is pre-
sented in Supplemental Materials.
Sensitivity and scenario analyses
Probabilistic sensitivity analysis (PSA) was performed to 
assess the uncertainties associated with key model param-
eters (see Supplemental Materials for detailed distribu-
tions used in PSA). Univariate one-way sensitivity analy-
sis (OWSA) was conducted to identify the most influential 
parameters. Finally, a wide range of scenario analyses 
were used to explore the uncertainty of the model results 
with regard to alternative model assumptions and sources 
of model inputs, including alternative parametric curves 
and assumptions regarding the maximum duration for 
nivolumab.
Results
Known (for ipilimumab) and assumed (for dabrafenib and 
vemurafenib) PAS discounts were included in the base case 
incremental cost-effectiveness results for BRAF −ve and 
BRAF +ve patients (see Table 2). For BRAF −ve patients, 
nivolumab is most effective [4.31 quality-adjusted life years 
(QALYs)] but also most costly (£97,898 discounted life-
time costs) compared to dacarbazine (£25,228 and 1.23 
QALYs) and ipilimumab (£57,158 and 2.64 QALYs). For 
dacarbazine, drug costs are low and the majority of the esti-
mated costs stem from subsequent ipilimumab treatment, 
Table 2  Base case incremental cost-effectiveness results for BRAF mutation-negative and BRAF mutation-positive patient populations
Incremental costs, LYG and QALYs are presented versus the next non-dominated comparator
ICER incremental cost-effectiveness ratio, LYG life years gained, QALYs quality-adjusted life years
Treatment Total costs (£) Total LYG Total QALYs Incremental 
costs (£)
Incremental LYG Incremental 
QALYs
ICER (£/QALY) incremental
BRAF mutation-negative patients
 Dacarbazine £25,228 1.74 1.23
 Ipilimumab £57,158 3.66 2.64 £31,930 1.92 1.41 £22,589
 Nivolumab £97,898 5.75 4.31 £40,740 2.09 1.66 £24,483
BRAF mutation-positive patients
 Ipilimumab £56,621 3.40 2.44
 Dabrafenib £71,511 2.37 1.69 £14,891 − 1.03 − 0.75 Excluded due to dominance
 Vemurafenib £74,001 2.37 1.70 £17,380 − 1.03 − 0.74 Excluded due to dominance
 Nivolumab £88,228 5.70 4.27 £14,227 3.33 2.56 £17,362
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monitoring/palliative care/end-of-life costs, costs for the 
management of AEs, and drug administration costs. The 
breakdown of the costs for dacarbazine is presented in the 
Supplemental Materials. There is no dominance or extended 
dominance, and the incremental cost-effectiveness ratios 
(ICERs) for nivolumab (against ipilimumab) and ipili-
mumab (against dacarbazine) are estimated to be £24,483 
and £22,589 per QALY gained, respectively. Therefore, 
nivolumab should be considered most cost-effective for 
BRAF −ve patients in England if the willingness-to-pay 
(WTP) threshold is above £24,483; ipilimumab should 
be considered most cost-effective if the WTP threshold 
is between £22,589 and £24,482; and dacarbazine should 
be considered most cost-effective if the threshold is below 
£22,589. NICE considered nivolumab to have met the cri-
teria for an ‘end of life’ treatment [15]; hence, a threshold 
of £50,000 per QALY is assumed to be relevant. Therefore, 
nivolumab is estimated to be the most cost-effective treat-
ment for BRAF −ve patients.
For BRAF +ve patients, nivolumab is also estimated 
to be most effective (4.27 QALYs) but also most costly 
(£88,228) compared to ipilimumab (£56,621 and 2.44 
QALYs), dabrafenib (£71,511 and 1.69 QALYs) and vemu-
rafenib (£74,001 and 2.37 QALYs). Both dabrafenib and 
vemurafenib are dominated by ipilimumab due to higher 
costs but lower QALYs compared to ipilimumab, and are, 
therefore, excluded as potential cost-effective treatments. 
The ICER for nivolumab (against ipilimumab, the only non-
dominated comparator) is estimated to be £17,362; there-
fore, nivolumab is also the most cost-effective treatment for 
BRAF +ve patients.
Cost-effectiveness acceptability curves (CEACs) are pre-
sented in Fig. 3 to show the probability of each treatment 
being the most cost-effective under different WTP thresh-
olds (up to £100,000) based on 1000 PSA runs of the base 
case. With a WTP of £50,000, the probability of nivolumab 
being most cost-effective is 95 and 99%, respectively, for the 
BRAF −ve and BRAF +ve patients.
The key drivers of cost-effectiveness identified by the 
OWSA include covariate-adjusted survival curves for TTP 
and PPS for nivolumab, ipilimumab, and dacarbazine, and 
TOT for nivolumab; parametric curves for OS and PFS for 
vemurafenib and long-term OS; statistical model for deriv-
ing health-state utilities; and drug administration costs for 
nivolumab, ipilimumab, and dacarbazine. The OWSA results 
showed that the base case cost-effectiveness results are not 
sensitive to the most impactful parameters. The tornado 
diagrams, based on the OWSA, depicting the 20 most influ-
ential model inputs for BRAF −ve patients are presented in 
Supplemental Materials.
In the range of scenario analyses performed, nivolumab 
remains the most cost-effective for the majority of scenar-
ios tested. Specifically, nivolumab remains cost-effective in 
scenarios for alternative parametric curves for TTP, PPS, 
TOT, and long-term OS; alternative data sources for indi-
rect treatment comparison; alternative sources for utility; 
and alternative maximum treatment durations of 3, 4, or 
5 years. Nivolumab is not cost-effective when there is a low 
discontinuation rate on nivolumab in Year 2 or when a high 
proportion of patients discontinue nivolumab treatment at 
Year 2 but are then assumed to have OS based on the registry 
data. However, these scenarios are not deemed clinically 
plausible based on expert opinion from UK clinicians.
Discussion
This economic evaluation was performed to help assess the 
cost-effectiveness of nivolumab monotherapy against all 
relevant comparators in England at the time of the analy-
sis, including ipilimumab and BRAF inhibitors, by syn-
thesising all relevant available evidence, including expert 
opinion. The base case ICERs estimated for nivolumab 
are £24,482 and £17,362 for BRAF −ve and BRAF +ve 
patients, respectively. These estimated ICERs are below 
the commonly assumed £50,000 NICE WTP threshold for 
end-of-life treatments. PSA estimates that the probability 
of nivolumab being most cost-effective compared to the 
comparators is 95 and 99% for BRAF −ve and BRAF +ve 
patients, respectively, given the WTP threshold of £50,000. 
Therefore, at the time of the analysis, nivolumab was con-
sidered a cost-effective treatment for advanced melanoma 
patients in England.
The PFS and OS estimated by the model for nivolumab 
and dacarbazine fit well with the pivotal CheckMate 066 
trial. The longest OS data for nivolumab come from a 
Phase I non-RCT (CheckMate 003), with follow-up for up 
to 6 years [36], but patient numbers are small, with 107 
advanced melanoma patients randomised to various doses 
Fig. 3  Cost-effectiveness acceptability curve for BRAF mutation-
negative patients
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of nivolumab and only 29, 15, and 3 at risk patients at Year 
4, 5, and 6, respectively. No other long-term OS data for 
nivolumab are currently available. The modelled long-term 
OS for nivolumab lies above the OS curve for ipilimumab, 
which was deemed clinically plausible, given the data and 
evidence available and the mode of action for nivolumab. A 
comparison of trial observations and model predictions is 
presented in Supplemental Materials.
A key driver for the cost-effectiveness of nivolumab is 
the assumed 2-year maximum treatment period. Threshold 
analyses suggested that nivolumab remains cost-effective at 
a £50,000 WTP threshold with maximum treatment periods 
up to 6 and 14 years for BRAF −ve and BRAF +ve patients, 
respectively. It is unlikely that patients would be treated by 
nivolumab for such long durations in clinical practice. The 
optimum treatment duration for immunotherapies such as 
nivolumab and pembrolizumab is an active research area.
A study reported in abstract form suggests that a state-
transition approach (based on TTP, PrePS, and PPS in this 
analysis) and an AUC approach would produce the same 
results [37]. The state-transition approach was chosen in 
the analysis, because OS data in CheckMate 066 were very 
immature for nivolumab, which made it difficult to esti-
mate robust OS parametric curves for extrapolation. The 
state-transition approach could mitigate the limitation by 
fitting a more “mature” PPS compared to OS, because PPS 
is based on deaths for patients who have progressed, while 
OS is based on deaths for all randomised patients (hence, 
PPS has a smaller denominator). Figure 4 compares the OS 
and corresponding PPS KM data for the nivolumab arm in 
CheckMate 066 and shows that there were 50 deaths out of 
210 randomised patients for the OS (median OS not reached) 
and 31 deaths out of 93 patients who had documented pro-
gression (median PPS is 10.9 months). The relative maturity 
of PPS could enable more reliable and robust extrapolation 
of survival beyond the trial period. The disadvantages are 
that PPS, compared to OS, is based on fewer data and that 
randomisation is not maintained for PPS as it is measured 
after progression.
The limitations of the study include the immature OS 
data from the pivotal trial, the lack of long-term OS data for 
nivolumab, the uncertainty regarding the treatment duration 
for nivolumab, and the lack of access to patient-level data 
for competitors’ treatments. Most limitations of this analysis 
are common in oncology modelling, especially economic 
models developed to support reimbursement submissions, 
where there is inevitable pressure to support rapid analysis 
to enable access to effective and cost-effective new therapies. 
Therefore, in many circumstances, an economic model has 
to be developed with relatively immature data. However, 
the existence of the long-term survival data for a broadly 
comparable treatment, ipilimumab [9], greatly increased 
the robustness and credibility of long-term OS estimates for 
ipilimumab and nivolumab in this analysis.
When more mature nivolumab OS data from CheckMate 
066 become available, it will be interesting to compare 
the state transition and the AUC methods using the same 
patient-level data. It will also be worthwhile to update the 
Fig. 4  Comparison of overall 
survival and post-progression 
survival for nivolumab in 
CheckMate 066. N total number 
of patients, n number of patients 
who died, OS overall survival, 
PPS post-progression survival
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model when evidence from real-world data for optimum 
treatment duration for immunotherapies is available.
Since the NICE approval of nivolumab, several other new 
treatments (e.g., nivolumab in combination of ipilimumab 
and pembrolizumab) have been approved by NICE for the 
treatment of advanced melanoma. Therefore, future analy-
sis would be meaningful to assess the cost-effectiveness of 
nivolumab monotherapy compared to these newly approved 
treatments which would become part of standard of care.
Alternative survival models that have the potential to 
model OS plateau (as estimated for the nivolumab and ipili-
mumab arms in this analysis) include spline models and 
mixture cure models. Future research on the application of 
these approaches will be insightful, especially when mature 
OS data become available.
The current analysis focuses on the cost-effectiveness of 
nivolumab for the treatment of advanced melanoma patients. 
The assessment of affordability or budget impact to the NHS 
in England for approving nivolumab in this indication by 
NICE was outside the scope of the cost-effectiveness analy-
sis. Nevertheless, the tension between restricted health care 
budgets and increasing expenditures makes the general 
affordability of new therapies an important issue for the 
NHS in England and payers in other countries alike. The 
question of affordability may be particularly prominent for 
therapies, such as immune-oncology agents, that can poten-
tially be approved in multiple indications within a short time 
span (e.g., nivolumab has been approved in the treatment of 
Hodgkin lymphoma, lung cancer, renal cell carcinoma, and 
head and neck cancer in England since this original analysis 
in advanced melanoma). It is not straightforward to assess 
the affordability of a particular treatment or type of treat-
ments as this involves careful consideration of the wider 
health care system and other contextual factors. Further 
research on how the affordability issue should be assessed 
would be valuable to help study the affordability of new 
treatments.
In conclusion, current evidence indicates that nivolumab 
is a cost-effective treatment for advanced melanoma patients 
in England and represents good value for public money spent 
by the NHS.
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